Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori : A Meta‐Analysis of Randomized Controlled Trials
JGH Open · 2025-03 · 9 (3)
DOI: 10.1002/jgh3.70134 ↗Abstract
ABSTRACT Introduction Concerns have been raised regarding the decreasing success rates of the standard treatment of Helicobacter pylori (proton pump inhibitor (PPI) and two/three antibiotics) and the long‐term effects carried by PPI. Despite conflicting data, Tegoprazan, a potassium‐competitive acid blocker, is hypothesized to be superior to PPI for eradicating H pylori . This systematic review and meta‐analysis aim to determine the superiority of Tegoprazan‐containing therapy to PPI‐containing therapy for H pylori eradication. Methods A systematic literature search identified studies published until December 12, 2024, from MEDLINE, EMBASE, SCOPUS, and CENTRAL. The search strategy included the following keywords: “Tegoprazan,” “ Proton Pump Inhibitors,” and “ Helicobacter pylori . ” Only randomized controlled trials (RCTs) that compared the efficacy of Tegoprazan to any PPI were included. Risk of bias assessment was performed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs. The random‐effect model was used to calculate the pooled risk ratio (RR) and its 95% Confidence Interval (95% CI) from the intention‐to‐treat population. Results Six RCTs with low risks of bias were included in this meta‐analysis. All studies included treatment‐naïve patients and compared first‐line H pylori treatment. The overall eradication rates of Tegoprazan‐containing ( N = 1052) versus PPI‐containing therapy ( N = 1058) were 83.37% and 80.06%, respectively (RR 1.045; 95% CI 1.008–1.084; I 2 = 0%). Tegoprazan‐containing therapy demonstrated comparable treatment‐emergent adverse event (TEAE) rates compared to PPI‐containing therapy (46.48% vs. 46.31%; RR 1.026; 95% CI 0.952–1.106; I 2 = 48%). Conclusion This meta‐analysis demonstrated that Tegoprazan‐containing therapy is superior to PPI‐containing therapy for first‐line H pylori eradication, with comparable safety profiles.
EUVIMED